Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 280

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Clinical significance of CD38 expression in chronic lymphocytic leukemia

Del Poeta, Giovanni, Maurillo, Luca, Venditti, Adriano, Buccisano, Francesco, Epiceno, Anna Maria, Capelli, Giovanni, Tamburini, Anna, Suppo, Giovanna, Battaglia, Alessandra, Del Principe, Maria Ilaria, Del Moro, Beatrice, Masi, Mario, Amadori, Sergio · 2001 · Blood

Abstract

B-cell chronic lymphocytic leukemia (B-CLL) follows heterogeneous clinical courses, and several biological parameters need to be added to the current clinical staging systems to predict which patients will experience an indolent or an aggressive outcome. This study analyzed CD38 expression by flow cytometry and soluble APO1/Fas (sAPO1/Fas), Bcl-2 (sBcl-2), and CD23 (sCD23) proteins by immunoenzymatic methods to evaluate their effect on the clinical course of 168 unselected B-CLL patients. Intermediate/high risk modified Rai stages were characterized by a higher CD38+ B-cell number (P = .0002) and higher sCD23 levels (P < .0001). Moreover, CD38+ B-cell percentages were significantly and directly associated both with β2-microglobulin and sCD23 concentrations (P < .0001 and P = .002, respectively). Both a higher tumor burden (lymphadenopathy/splenomegaly) and a lymphocyte doubling time less than 12 months were significantly associated with higher CD38+ percentages (P < .0001 and P = .0001, respectively). With regard to clinical outcome, progression-free survival was significantly longer (75% versus 37% at 5 years; P = .00006) in patients with lower CD38+ B-cell percentages. Furthermore, the risk of partial or no response to fludarabine increased with increasing CD38 expression (P = .003), and a shorter overall survival (50% versus 92% at 8 years; P < .00001) characterized patients with more than 30% CD38+ B-cell number. The predictive value of CD38 expression was maintained among the patients within the Rai intermediate risk group and was confirmed in multivariate analysis. Thus, the percentage of CD38+ B cells appears to be an accurate predictor of clinical outcome and therefore could be used to indicate when more novel chemotherapeutic approaches are needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.v98.9.2633

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 280

Metadata

Authors
Del Poeta, G., Maurillo, L., Venditti, A., Buccisano, F., Epiceno, A. M., Capelli, G., Tamburini, A., Suppo, G., Battaglia, A., Del Principe, M. I., Del Moro, B., Masi, M., & Amadori, S.
Venue
Blood
Published
2001-11-01
Volume
98
Issue
9
Pages
2633-2639
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2100200868
Cited by
280
References
29
FWCI
7.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical significance of CD38 expression in chronic lymphocytic leukemia. https://app.cochat.ai/papers/10.1182/blood.v98.9.2633
The paper
Del Poeta, G., Maurillo, L., Venditti, A., Buccisano, F., Epiceno, A. M., Capelli, G., Tamburini, A., Suppo, G., Battaglia, A., Del Principe, M. I., Del Moro, B., Masi, M., & Amadori, S. (2001). Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood. https://doi.org/10.1182/blood.v98.9.2633

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.